← Eichor
Condition: Unresectable Or Metastatic Hepatocellular Carcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Unresectable Or Metastatic Hepatocellular Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

TheraSphere Japan Pre-Market Study
NA · 4 location(s) · Boston Scientific Corporation · NCT07377487Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Phase 1 · 122 location(s) · Exelixis · NCT05176483A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectab
Phase 1/Phase 2 · 21 location(s) · Tvardi Therapeutics, Incorporated · NCT05440708Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatmen
Phase 1/Phase 2 · 49 location(s) · Pfizer · NCT07227012Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellu
Phase 2 · 14 location(s) · CatalYm GmbH · NCT07219459Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Phase 2 · 12 location(s) · Replimune, Inc. · NCT05733598Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381FGF19 Overexpression Combination Unified Study in HCC-19
Phase 2 · 1 location(s) · RenJi Hospital · NCT06978933A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular
Phase 2/Phase 3 · 2 location(s) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · NCT07490262Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metast
Phase 2 · 16 location(s) · Academic and Community Cancer Research United · NCT05168163Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07500220
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.